Compounded tirzepatide produces more weight loss, but compounded semaglutide costs less and has a clearer regulatory pathway. If budget is your primary concern, semaglutide wins at $146-249/month. If you want maximum efficacy and can afford $199-375/month, tirzepatide's dual-mechanism advantage holds up in compounded form. Both require a prescription and medical supervision. The biggest factor most people overlook: tirzepatide's compounding status faces more regulatory uncertainty.
If you've decided to go the compounded route for GLP-1 treatment, you face the same fundamental choice as brand-name patients: semaglutide or tirzepatide? The clinical differences between the molecules carry over to compounded versions, but the pricing, availability, and regulatory landscape look very different.
The Compounded Pricing Comparison
| Factor | Compounded Semaglutide | Compounded Tirzepatide |
|---|---|---|
| Typical monthly cost | $146-249/mo ✓ | $199-375/mo |
| Lowest available price | ~$146/mo ✓ | ~$199/mo |
| All-inclusive (consult + meds) | $179-299/mo ✓ | $249-399/mo |
| Available formats | Injectable, drops, troches, sublingual | Injectable, drops, lozenges |
| Providers offering it | More providers ✓ | Fewer providers |
Why the price difference? Semaglutide requires lower doses (measured in milligrams), while tirzepatide doses range up to 15mg — more active ingredient per dose means higher compounding costs. Additionally, more providers compete in the semaglutide space, which drives prices down.
Efficacy: Does the Brand-Name Advantage Hold?
The head-to-head clinical data comes from brand-name studies (SURMOUNT-5 compared Zepbound to Wegovy), not compounded formulations. However, because compounded versions use the same active molecules, the pharmacological advantage of tirzepatide's dual GLP-1/GIP mechanism should carry over.
| Outcome (from brand-name data) | Semaglutide | Tirzepatide |
|---|---|---|
| Average body weight loss | ~15% | ~20% ✓ |
| On a 220 lb person | ~33 lbs | ~44 lbs ✓ |
| A1C reduction (diabetic patients) | 1.5-2.0% | 2.0-2.3% ✓ |
| Patients achieving ≥20% loss | ~23% | ~55% ✓ |
Important caveat: Compounded medications don't undergo the same rigorous clinical trials as brand-name drugs. Bioavailability may vary between compounding pharmacies. The efficacy data above represents the molecules at their best — your individual results with compounded versions may differ based on pharmacy quality and formulation.
The Regulatory Reality
This is the factor most comparison articles ignore, and it's arguably the most important one.
Compounded Semaglutide
As of March 2026, semaglutide remains on the FDA drug shortage list. This is significant because compounding pharmacies can legally prepare compounded versions of drugs that are in shortage, under FDA enforcement discretion.
The FDA has taken enforcement action against some compounding pharmacies for semaglutide, particularly 503A pharmacies after the initial shortage resolution in February 2025. However, ongoing supply issues have kept the drug on the shortage list, providing continued legal cover for many compounders.
Compounded Tirzepatide
Tirzepatide's regulatory path has been rockier. The FDA resolved the tirzepatide shortage in October 2024, which triggered enforcement deadlines for 503A pharmacies (immediate) and 503B outsourcing facilities (March 2025). Courts have intervened with temporary injunctions, and the situation remains fluid.
The practical impact: fewer providers offer compounded tirzepatide compared to semaglutide, and those that do operate in a grayer regulatory area. This doesn't mean compounded tirzepatide is illegal — it means the legal landscape is less settled.
Available Formats Compared
One advantage of compounded medications: variety. Unlike brand-name options (limited to injectable pens and, for Wegovy, an oral pill), compounded GLP-1s come in multiple delivery formats:
| Format | Comp. Semaglutide | Comp. Tirzepatide |
|---|---|---|
| Subcutaneous injection | ✅ Most common | ✅ Most common |
| Oral drops | ✅ Available | ✅ Available |
| Sublingual troches | ✅ Available | Limited |
| Lozenges | Available | ✅ Available (SHED, others) |
| Topical cream | Rare | Rare |
Injectable remains the gold standard for bioavailability and consistent dosing. Non-injectable formats (drops, troches, lozenges) offer convenience but may have lower and more variable absorption rates.
Compare Top Compounded GLP-1 Providers
Affiliate links · Prices verified March 2026
Side Effect Comparison
Both compounded medications carry the same side effect profiles as their brand-name counterparts — the active molecules are identical. The most common issues are gastrointestinal:
Compounded semaglutide: Nausea (40-44%), diarrhea (~30%), vomiting (~24%), constipation (~24%). Typically worst during dose titration and improving over weeks 4-8.
Compounded tirzepatide: Generally similar GI side effects but some studies suggest slightly lower nausea rates (24-33%). The dual-receptor mechanism may distribute metabolic effects differently.
The difference with compounded formulations: your compounding pharmacy's formulation quality matters. Reputable 503B outsourcing facilities with cGMP practices and batch testing tend to produce more consistent products than smaller 503A pharmacies.
Who Should Choose Compounded Semaglutide
Budget is the top priority. At $146-249/month, compounded semaglutide is the most affordable GLP-1 pathway period — cheaper than brand-name oral Wegovy ($149) when you factor in consultation fees.
You want the most established regulatory footing. Semaglutide's ongoing shortage status provides clearer legal cover for compounding pharmacies.
You want the widest provider selection. More telehealth platforms offer compounded semaglutide, which means more competition and better pricing.
You're risk-averse about regulatory changes. Even if compounding rules shift, semaglutide has more pathways to remain available.
Who Should Choose Compounded Tirzepatide
Maximum weight loss is non-negotiable. If you want the most effective molecule available and can afford the premium, tirzepatide's dual-mechanism advantage is real.
You've plateaued on semaglutide. Switching from a single-receptor to dual-receptor agonist is a legitimate clinical strategy for patients who've stopped responding to semaglutide.
You need strong A1C reduction. For patients with type 2 diabetes who want both weight loss and glycemic control, tirzepatide's superior A1C reduction provides meaningful clinical benefit.
You're comfortable with regulatory uncertainty. Compounded tirzepatide exists in a more fluid regulatory space. If your provider loses the ability to supply it, you'll need a backup plan.
How to Choose a Compounding Provider
Regardless of which molecule you choose, the quality of your compounding pharmacy matters enormously. Look for:
503B outsourcing facility (preferred). These facilities operate under FDA oversight with mandatory cGMP compliance and batch testing. They're the closest thing to brand-name quality in the compounding world.
PCAB accreditation. The Pharmacy Compounding Accreditation Board sets voluntary quality standards. PCAB-accredited pharmacies undergo regular inspections.
Third-party testing documentation. Reputable providers will share (or make available upon request) certificates of analysis showing potency, sterility, and endotoxin testing results.
Transparent all-in pricing. The best compounded GLP-1 providers include consultation, medication, shipping, and ongoing medical supervision in one monthly price. If a provider separates these into multiple fees, calculate the total before committing.
Quick Decision Matrix
| Your Priority | Choose |
|---|---|
| Lowest possible monthly cost | Compounded semaglutide |
| Maximum weight loss results | Compounded tirzepatide |
| Most stable regulatory environment | Compounded semaglutide |
| Switching from failed semaglutide | Compounded tirzepatide |
| Non-injectable format options | Both (sema has more options) |
| Strongest A1C reduction | Compounded tirzepatide |
| Widest provider selection | Compounded semaglutide |
Both compounded options offer effective, affordable GLP-1 treatment. The right choice depends on your clinical goals, budget tolerance, and comfort with the evolving regulatory landscape.